Nifedipine pharmacokinetics and plasma levels in the management of preterm labor

American Journal of Therapeutics

Volumn 14, Issue 4, 2007, Pages 346-350

  Papatsonis, Dimitri N M ^a,d   Bos, Jacqueline M ^b   Van Geijn, Herman P ^a   Lok, Christianne A R ^a   Dekker, Guus A ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d AMPHIA HOSPITAL   (Netherlands)

Author keywords

Nifedipine; Pharmacokinetics; Plasma levels; Preterm labor

Indexed keywords

NIFEDIPINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; FLUSHING; HEART RATE; HUMAN; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TOCOLYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; FEMALE; HUMANS; NIFEDIPINE; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PULSE; TOCOLYTIC AGENTS;

EID: 34547690779     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000209679.76335.df     Document Type: Article

References (26)

1. Berkowitz GS, Papiernik E. Epidemiology of preterm birth. Epidemiol Rev. 1993;15:414-443.
2. Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early Hum Dev. 1999;53:193-218.
3. Ulmsten U, Andersson KR, Wingerup L. Treatment of premature labor with the calcium antagonist nifedipine. Arch Gynecol. 1980;229:1-5.
4. Tsatsaris V, Papatsonis DNM, Goffinet F, et al. Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis. Obstet Gynecol. 2001;97:840-847.
5. Ray JG. Meta-analysis of nifedipine versus beta-sympathomimetic agents for tocolysis during preterm labour. J SOGC. 1998;20:259-269.
6. King JF, Flenady VJ, Papatsonis DN, et al. Calcium channel blockers for inhibiting preterm labour (Cochrane Review). Cochrane Database Syst Rev. 2003;1:CD002255.
7. Ferguson JE, Schutz T, Pershe R, et al. Nifedipine pharmacokinetics during preterm labor tocolysis. Am J Obstet Gynecol. 1989;161:1485-1490.
8. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest. 1992;90:1871-1878.
9. Kroemer HK, Gautier JC, Beaune P, et al. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993;348:332-337.
10. Pichard L, Gillet G, Fabre I, et al. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos. 1990;18:711-719.
11. Guengerich FP, Brian WR, Iwasaki M, et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem. 1991;34:1838-1844.
12. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341:1447-1457.
13. Caritis SN, Darby MJ, Chan L. Pharmacologic treatment of preterm labor. Clin Obstet Gynecol. 1988;31:635-651.
14. Ray D, Dyson DC. Calcium channel blockers. Clin Obstet Gynecol. 1995;38:713-721.
15. Follath F, Taeschner W. Clinical pharmacology of calciun antagonists. J Cardiovasc Pharm. 1988;12:S98-S100.
16. Kelly J, O'Malley K. Clinical pharmacokinetics of cacium antagonists, an update. Clin Pharmacokin. 1992;22:416-433.
17. Piepho R. Individualization of calcium entry-blocker dosage for systemic hypertension. Am J Cardiol. 1985;56:105H-111H.
18. Reid J, Meredith P, Donnelly R, et al. Pharmacokinetics of calcium antagonists. J Cardiovasc Pharm. 1988;12:S22-S26.
19. Sorkin EM, Clissold SP, Brogden RN. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischemin heart disease, hypertension and related cardiovascular disorders. Drugs. 1985;30:182-274.
20. van Wisse M. Tweede generatie calcium antagonisten. Pharma Selecta. 1991;7:13-20.
21. Kleinbloesem CH, van Brummelen P, van de Linde JA, et al. Nifedipine kinetics and dynamics in healthy subjects. Clin Pharm Ther. 1984;35:742-749.
22. Harake B, Gilbert RD, Ashwal S, et al. Nifedipine: effects on fetal and maternal hemodynamics in pregnant sheep. Am J Obstet Gynecol. 1987;157:1003-1008.
23. Prevost RR, Akl SA, Whybrew WD, et al. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy. 1992;12:174-177.
24. Foster TS, Hamann SR, Richards VR, et al. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol. 1983;23:161-170.
25. Tsatsaris V, Cabrol D, Carbonne B. Pharmacokinetics of tocolytic agents. Clin Pharmacokinet. 2004;43:833-844.
26. Papatsonis DNM, Van Geijn HP, Bleker OP, et al. Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. Int J Gynecol Obstet. 2003;82:5-10.